semaglutide and crohn's disease Glucagon-like peptide-1 (GLP-1) receptor agonists in inflammatory bowel disease: mechanisms, clinical implications, therapeutic potential Crohn's Disease Treatment - ColoWell

Association of sodium-glucose cotransporter-2 inhibitors with outcomes in type 2 diabetes with reduced and preserved left ventricular ejection fraction: analysis from the CVD-REAL 2 study

Headaches were not even listed as a common side effect in the FDA labeling for Zepbound, the weight management version of tirzepatide

It is well established that multiple GLP-1RA treatments increase levels of blood pancreatic enzymes (amylase, lipase) as measured by laboratory assay, including in the STEP 1 trial 20

6 Estimated effect sizes of rs1800437 across study phenotypes

While both options can lead to significant weight loss, one relies on ongoing medication support and the other involves permanent surgical changes to the digestive system